CAVAN FOLATE DHA
-
folic acid, .beta.-carotene, cholecalciferol, ascorbic acid, .alpha.-tocopherol acetate, dl-, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, niacinamide, calcium carbonate, ferrous fumarate, magnesium oxide, zinc oxide, cupric oxide and doconexent
Seton Pharmaceuticals
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------
Cavan™-Folate DHA is a prescription prenatal/postnatal multivitamin/mineral tablet and a softgel with an essential fatty acid.
|
|
Each tablet has the following active ingredient: | |
---|---|
Vitamin B9 | 1 mg |
Each tablet also contains the following ingredients for nutritional supplementation: | |
Vitamin A (beta carotene) | 2700 IU |
Vitamin D (cholecalciferol) | 400 IU |
Vitamin C (ascorbic acid) | 70 mg |
Vitamin E (dl-alpha tocopheryl acetate) | 30 IU |
Vitamin B1 (thiamine mononitrate) | 1.6 mg |
Vitamin B2 (riboflavin) | 1.8 mg |
Vitamin B6 (pyridoxine hydrochloride) | 2.5 mg |
Vitamin B12 (cyanocobalamin) | 12 mcg |
Niacin (niacinamide) | 18 mg |
Calcium (calcium carbonate) | 100 mg |
Elemental Iron (ferrous fumarate) | 65 mg |
Magnesium (magnesium oxide) | 25 mg |
Zinc (zinc oxide) | 25 mg |
Copper (copper oxide) | 2 mg |
Each softgel has the following active ingredient: | |
Docosahexaenoic Acid (DHA) | 250 mg* |
PVP K30, Sodium Phosphate Dibasic, Potassium Chloride, Fumed Silica, Citric Acid, TriPotassium Citrate, Microcrystalline Cellulose, Croscarmellose Sodium, Magnesium Stearate, Stearic Acid, Gum Arabic, Carboxylmethyl Cellulose, Prosolv™, Maltodextrin, Silicon Dioxide, Pregelatinized Starch, Hypromellose, Polyethylene Glycol, Ethyl Cellulose, Titanium Dioxide, Talc, FD&C Blue #1, Vegetable Oil, Polysorbate 80, Vitamin E, Natural Creamy Orange Flavor, Gelatin, Glycerin and Purified Water.
Cavan™-Folate DHA is indicated for the supplemental requirements of patients with nutritional deficiencies or are in need of nutritional supplementation.
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients, including fish or fish oil.
Daily ingestion of more than 3 g per day of omega-3 fatty acids (ALA, EPA, and DHA) from fish oils may have potential antithrombotic activities, or effects, and may increase bleeding times. Administration of omega-3 fatty acids − including DHA, should be avoided in patients with inherited or acquired bleeding diatheses, including those taking anticoagulants.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Exercise caution to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.
Folates (including folic acid and reduced folates), when administered as a single agent in doses above 0.1 mg daily, may obscure the detection of B12 deficiency (specifically, the administration of folic acid may reverse the hematological manifestations of B12 deficiency, including pernicious anemia, while not addressing the neurological manifestations). Reduced folates may be less likely than folic acid to mask vitamin B12 deficiency. Folate therapy alone is inadequate for the treatment of B12 deficiency.
Cavan™-Folate DHA is a prescription vitamin for use only under the direction and supervision of a licensed physician.
Drugs which may interact with folate include:
Drugs which may interact with pyridoxine hydrochloride:
Pyridoxine hydrochloride should not be given to patients receiving the drug levodopa, because the action of levodopa is antagonized by pyridoxine hydrochloride. However, pyridoxine hydrochloride may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa
Allergic sensitization has been reported following both oral and parenteral administration of folic acid, as well as possibly the use of other forms of folates – including reduced folates. Paresthesia, somnolence, nausea and headaches have been reported with pyridoxine hydrochloride. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body have been associated with cyanocobalamin.
Before, during and after pregnancy, one tablet and one softgel capsule daily, or as directed by a physician.
Cavan™-Folate DHA is supplied in child-resistant blister packs of 30 tablets and 30 softgels. The Cavan™-Folate DHA tablet is an oblong, blue coated tablet with "S124" debossed on one side. The DHA softgel is an oblong, clear softgel capsule.
NDC 13925-125-60
Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.
KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
Rx Only
Reserved for Professional Recommendation
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.
Manufactured For:
Seton Pharmaceuticals
Manasquan, NJ 08736
1-800-510-3401
MADE IN CANADA
06/10
SETON
PHARMACEUTICALS
NDC 13925-125-60
Cavan TM- Folate
DHA
Tablets/Softgels
Rx Only
30-Day Supply
30 Tablets / 30 Softgels
SETON
PHARMACEUTICALS
CAVAN FOLATE DHA
folic acid, .beta.-carotene, cholecalciferol, ascorbic acid, .alpha.-tocopherol acetate, dl-, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, niacinamide, calcium carbonate, ferrous fumarate, magnesium oxide, zinc oxide, cupric oxide and doconexent kit |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
unapproved drug other | 06/04/2010 | 03/31/2012 |
Labeler - Seton Pharmaceuticals (828898002) |
Registrant - Seton Pharmaceuticals (828898002) |
Establishment | |||
Name | Address | ID/FEI | Operations |
VIVA | 253288898 | MANUFACTURE |
Establishment | |||
Name | Address | ID/FEI | Operations |
Rainbow Gold | 800695152 | REPACK |
Revised: 08/2012 Seton Pharmaceuticals